NewAmsterdam Pharma Company N.V./$NAMS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Ticker

$NAMS
Sector
Health
Primary listing
NASDAQ

Employees

68
Headquarters
Naarden, Netherlands
Website
www.newamsterdampharma.com

NAMS Metrics

BasicAdvanced
$4B
-
-$1.55
-0.01
-

Bulls say / Bears say

Late-breaking BROADWAY and TANDEM Phase 3 trial results presented at the European Atherosclerosis Society Congress—and published simultaneously in The New England Journal of Medicine and The Lancet—confirmed significant reductions in LDL-C, with a safety profile similar to placebo, highlighting obicetrapib’s unique efficacy and tolerability.
The European Medicines Agency validated Marketing Authorization Applications for both 10 mg obicetrapib as monotherapy and as a fixed-dose combination with ezetimibe in August 2025, moving the drug forward in the regulatory review process and preparing for a potential launch in Europe.
A prespecified analysis of Alzheimer’s disease biomarkers presented at AAIC in July 2025 showed obicetrapib significantly lowered plasma p-tau217 levels (p=0.0019) across all patients and in ApoE4 carriers (p=0.0215), indicating possible neuroprotective effects in addition to lowering cholesterol.
Selling, general, and administrative expenses rose 65.5% year-over-year to $27.3 million in Q2 2025 as NewAmsterdam expanded its commercial operations, increasing cash outflows before product revenue begins.
Under the Menarini license, NewAmsterdam may receive up to €863 million in milestone payments and tiered royalties from European sales, which introduces revenue uncertainty due to the lack of definite product launch dates.
NewAmsterdam's shares are trading near a 52-week high of $27.29 with a forward P/E of 14.72, suggesting limited upside unless more positive clinical developments emerge.
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NAMS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs